Human iPSC-derived Mesenchymal Stem Cells
Mesenchymal stem cells (“MSCs”) are non-haematopoietic, multipotent stromal stem cells that can differentiate into a variety of cell types, including: osteoblasts, chondrocytes, myocytes, and adipocytes. Tempo-iMSCTM are human iPSC-derived mesenchymal stem cells. Tempo-iMSCTM express cell surface markers such as CD73, CD90, CD166, and CD105, in addition to Oct4 and Nanog. This expression profile is predictive of the long-term proliferative capacity of cultured human MSCs (see reference: here). MSCs have immunomodulatory features, secrete cytokines and immune-receptors which regulate the microenvironment in the host tissue and they have multi-lineage potentials for a variety of cell types. MSCs can be used in a variety of screening applications, from screening biologics and small molecules to siRNAs. Due to MSCs’ ability to self-renew (= growth without differentiation), they are easily scalable for running large-scale assays.
NEW! For scientists working on exosomes, please email us for conditional media for exosome extractions and biomarker validations.
NEW! For scientists working on CD34+ HSCs, please email us regarding Tempo-iHSCTM (SKU214; Custom Requests Only).
Tempo-iMSC™ Immunocytochemistry: anti-human-Nanog (CST)
Tempo-iMSC™ Immunocytochemistry: anti-human-Oct4 (CST)
Tempo-iMSC™ RT-PCR data (left-to-right): CD90/Thy1, CD105, CD166, Oct4, Nanog
Tempo-iMSC™, monolayer, 9 days post-thaw
Tempo-iMSC™, monolayer, 10 days post-thaw
Tempo-iMSC™ are intended for basic scientific research, drug discovery and therapeutics development use only. It is not a product for human testing or diagnostics.
Biomarker discoveries and validations
In vitro assays using MSCs (e.g., cytokine release assays)
Large-scale compound screenings
Lineage differentiation studies
~1.25 x10^6 cells per 1ml of freezing medium (vial)
Long-term Storage: liquid nitrogen
Growth Properties: adherent monolayer
Storage: remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Technology used: in-house developed proprietary serum-free, virus-free, nucleic-acids-free, feeder-free, and integration-free technology.
Starting Materials: human dermal/fibroblast cells
QC: Sterility, Safety (BioSafety Level 2), HIV/viruses, bacteria, fungi: negative. Cell viability post-thawing (>90%)
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and...
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for...
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets,...